NeoGenomics Yönetim

Yönetim kriter kontrolleri 3/4

NeoGenomics CEO'su Chris Smith, Aug2022 tarihinde atandı, in görev süresi 2.25 yıldır. in toplam yıllık tazminatı $ 11.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.6% maaş ve 91.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.5% ine doğrudan sahiptir ve bu hisseler € 9.16M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 3.8 yıldır.

Anahtar bilgiler

Chris Smith

İcra Kurulu Başkanı

US$11.7m

Toplam tazminat

CEO maaş yüzdesi	8.6%
CEO görev süresi	2.3yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Smith'un ücretlendirmesi NeoGenomics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$78m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$12m	US$1m	-US$88m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$15m	US$346k	-US$144m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 11.67M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.62M ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chris Smith (61 yo)

2.3yrs

Görev süresi

US$11,665,946

Tazminat

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% € 9.2m
Jeffrey Sherman	Chief Financial Officer	1.9yrs	US$3.55m	0.12% € 2.1m
Vishal Sikri	President of Advanced Diagnostics	2.8yrs	US$2.37m	0.10% € 1.8m
Melody Harris	President & COO of Informatics	1.9yrs	US$4.69m	0.084% € 1.5m
Warren Stone	Chief Commercial Officer	2yrs	US$3.01m	0.078% € 1.4m
Gregory Aunan	Chief Accounting Officer	1.5yrs	Veri yok	0.011% € 204.8k
Kendra Sweeney	Vice President of Investor Relations & Communications	no data	Veri yok	Veri yok
Alicia Olivo	Executive VP of Business Development	2.6yrs	Veri yok	0.033% € 597.0k
Hutan Hashemi	Chief Compliance Officer	2.6yrs	Veri yok	Veri yok
Derek Lyle	Chief Medical Officer	3.8yrs	Veri yok	Veri yok
Gary Passman	Chief Culture Officer	1.8yrs	Veri yok	Veri yok
Kareem Saad	Head of Strategy & Transformation	less than a year	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: NG9 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% € 9.2m
Michael Kelly	Independent Director	4.3yrs	US$317.50k	0.025% € 449.9k
Lynn Tetrault	Independent Chair of the Board	9.4yrs	US$365.00k	0.048% € 869.7k
Bernard Fox	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Riccardo Dalla-Favera	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Anthony Zook	Independent Director	1.4yrs	US$276.23k	0.0088% € 160.6k
Steven Rosen	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
James Downing	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Stephen Kanovsky	Independent Director	7.3yrs	US$309.20k	0.028% € 511.3k
Razelle Kurzrock	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Alison Hannah	Member of Scientific Advisory Board & Independent Director	9.4yrs	US$305.00k	0.093% € 1.7m
Mark Rubin	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NG9 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

NeoGenomics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

Recent updates

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2023)

Neogenomics, Inc. Revises Full-Year 2024 Guidance

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2023)

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2023)

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$0.70 loss per share (vs US$1.16 loss in FY 2022)

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.30 loss in 3Q 2022)

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 2Q 2022)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.07 loss in FY 2021)

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.30 loss per share (vs US$0.17 loss in 3Q 2021)

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.64 profit in 2Q 2021)

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.19 loss in 1Q 2021)

High number of new and inexperienced directors

NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022

NeoGenomics, Inc. Provides Revenue Guidance for the First Quarter 2022

NeoGenomics, Inc. Announces Management Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Neogenomics, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

CEO & Director recently bought €462k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.023 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.063 loss in 2Q 2020)

High number of new and inexperienced directors

President of Pharma Services Division recently sold €6.7m worth of stock

Independent Director Raymond Hipp has left the company

Director Steven Jones has left the company

President of Clinical Services Division recently sold €117k worth of stock

Chief Medical Officer has left the company

First quarter 2021 earnings released: US$0.19 loss per share (vs US$0.067 loss in 1Q 2020)

NeoGenomics, Inc. Announces Chief Executive Officer Changes

Full year 2020 earnings released: EPS US$0.038 (vs US$0.08 in FY 2019)